Tenderwize
Retour à la recherche

Eribulin (ATC: L01XX41)

AOK Nordost - Die Gesundheitskasse·Potsdam, Germany·Deadline Feb 21, 2027 · 179 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V für die KV-Region Berlin

70/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

70 / 100

Complexité

30 / 100

Facteurs de risque

Automatic contract termination if another regional/national discount contract for the same active substance enters into...

Short contract duration (max 9 months) and potential for early termination reduce planning certainty and may not justif...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for oncological parenteral preparations from finished medicinal products
  • Active substance: Eribulin (ATC L01XX41)
Afficher le résumé complet

Open-House model for non-exclusive discount agreements under §130a Abs. 8c SGB V for oncology parenteral preparations in the Berlin region, open to all eligible pharmaceutical companies. One lot (Eribulin, ATC L01XX41). No selection competition – contracts awarded to all qualifying bidders. Rolling submission deadlines until 21.02.2027. No estimated value disclosed. Short contract duration (approx. 9 months).

Risques

Automatic contract termination if another regional/national discount contract for the same active substance enters into...

Short contract duration (max 9 months) and potential for early termination reduce planning certainty and may not justif...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company

Administrative

  • Submit signed contract in Schriftform (handwritten signature) in duplicate
  • Submit filled file 'OHV_8c_Berlin_Festlegung_[Wirkstoffname]_PZN' electronically via DTVP portal

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Potsdam, DEU

Site web

www.aok.de

Identifiant

DE275390265

Activité

Health

Lots (1)

LOT-0001

Eribulin (ATC: L01XX41)

Non-exclusive discount agreement for Eribulin (ATC L01XX41) for parenteral preparations in oncology for the Berlin region. Open-House model, no selection. Contracts executed with all qualified pharmaceutical companies. Earliest start 01.08.2026, end 30.04.2027. Automatic termination if a comparable regional/national discount contract enters into force.

SuppliesEU fundedElectronic submission

Localisation

Germany

Durée

Jul 2026 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 21, 2027

Détails de la procédure

Date de publication
14 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
332623-2026

Documents (2)

Appels d'offres similaires